← 產業報告目錄
Recombinant Human Endostatin Market Size, Share & Trends Analysis Report By Type (purity 95% and others) And By Application (medical care, scientific research and others), By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-27頁數 170報告編號 INSIGHTACE-ab4524cd5a
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
With a 2023 valuation of USD 133.3 Mn, the global Recombinant Human Endostatin Market is projected to increase to USD 249.4 Mn by 2031, demonstrating a CAGR of 8.3% during the 2024–2031 forecast window.
Recombinant Human Endostatin covers a naturally occurring protein in the human body that prevents angiogenesrepresents and has been bioengineered. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Recombinant Human Endostatin Market Snapshot
Chapter 4. Global Recombinant Human Endostatin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Purity 95%
5.2.2. Others
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Medical Care
6.2.2. Scientific Research
6.2.3. Others
Chapter 7. Recombinant Human Endostatin Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.1.2. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.1.3. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.2. Europe
7.2.1. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.2.2. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.2.3. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.3.2. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.3.3. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.4. Latin America
7.4.1. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.4.2. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.4.3. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
7.5.2. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
7.5.3. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Pfizer Inc.
8.2.2. Novus Biologicals
8.2.3. Biocon
8.2.4. Thermo Fisher Scientific
8.2.5. Yantai Medgenn Ltd.
8.2.6. FUJIFILM KYOWA KIRIN BIOLOGICS Co. Ltd.
8.2.7. PeproTech, Inc.
8.2.8. Onyx Pharmaceuticals, Inc.
8.2.9. Genexine, Inc.
8.2.10. Hetero.
8.2.11. Intas Pharmaceuticals Ltd.
8.2.12. Novartis AG.
8.2.13. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們